Orient Pharma Co., Ltd. (TPEX:4166)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
25.35
-0.75 (-2.87%)
At close: Mar 2, 2026
-32.85%
Market Cap 6.16B
Revenue (ttm) 1.28B
Net Income (ttm) 127.99M
Shares Out 243.04M
EPS (ttm) 0.57
PE Ratio 44.64
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 603,316
Average Volume 165,507
Open 26.30
Previous Close 26.10
Day's Range 25.20 - 26.35
52-Week Range 22.30 - 40.00
Beta 0.10
RSI 34.30
Earnings Date Mar 20, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan. [Read more]

Sector Healthcare
Founded 2008
Employees 173
Stock Exchange Taipei Exchange
Ticker Symbol 4166
Full Company Profile

Financial Performance

In 2024, Orient Pharma's revenue was 1.22 billion, an increase of 37.41% compared to the previous year's 889.91 million. Earnings were 107.37 million, an increase of 381.76%.

Financial Statements

News

There is no news available yet.